Enhancement on PharmaPoint: Acute Coronary Syndrome – 5EU Drug Forecast and Market Analysis to 2023

“The Report PharmaPoint: Acute Coronary Syndrome – 5EU Drug Forecast and Market Analysis to 2023 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. – MarketResearchReports.biz”

GlobalData estimates that the total market size for the 7MM in 2013 was $12.3bn, comprised of $5.0bn in branded drug sales (40%) and $7.3bn in generic sales (60%). GlobalData expects that the ACS drug market will grow at a CAGR of 13.4% over the ten year forecast period, resulting in a market value of $43.4bn by 2023, of which 64% will be attributed to branded drug sales ($27.7bn) and 36% to generic drug sales ($15.7bn). The current ACS market primarily comprised of antithrombotics, antihypertensives, and statins is flush with well-established standard-of-care therapies, many of which are generic. Therefore, the pipeline therapies that show the most promise exploit novel mechanisms of action and target orphan biochemical pathways. The ACS market will be driven by an aging population with a preponderance of lifestyle-based diseases, such as obesity, and the growing prevalence of metabolic disorders such as diabetes. The expansion of biologics into the ACS mainstream during the ten year forecast period is expected to significantly and fundamentally alter the ACS market, both medically and financially.

View Report At :http://www.marketresearchreports.biz/analysis/223229

France represents one of the smallest in terms of overall ACS drug sales. Next to the US market, Germany commands the largest global market share for the sale of ACS drugs. Italys contribution to global sales in both 2013 and 2023 falls in the middle of the sales distribution for the 7MM covered in this forecast. Of the 7MMs that were forecast in this report, Spains share of global sales is the smallest for both the 2013 base year and the final forecast year of 2023. Of the markets forecast here, the UK commands the third largest market share in both the 2013 base year and in 2023.


  • Overview of ACS including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

  • Detailed information on the key drugs in 5EU including product description, safety and efficacy profiles as well as a SWOT analysis.

  • Sales forecast for the top drugs in 5EU (the UK, France, Italy, Spain, Germany) from 2013-2023.

  • Analysis of the impact of key events as well the drivers and restraints affecting the 5EU ACS market.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return.

  • Stay ahead of the competition by understanding the changing competitive landscape for ACS.

  • ffectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential.

  • Make more informed business decisions from insightful and in-depth analysis of drug performance.

  • Obtain sales forecast for drugs from 2013-2023 in 5EU (the UK, France, Italy, Spain, Germany).

Download Sample copy of this Report at: http://www.marketresearchreports.biz/sample/sample/223229

Table of Contents

1 Table of Contents

1 Table of Contents 6

1.1 List of Tables 11

1.2 List of Figures 15

2 Introduction 16

2.1 Catalyst 16

2.2 Related Reports 17

2.3 Upcoming Related Reports 19

3 Disease Overview 20

3.1 Etiology and Pathophysiology 21

3.1.1 Etiology 21

3.1.2 Pathophysiology 25

3.1.3 Prognosis 26

3.1.4 Quality of Life 27

3.2 Symptoms 27

4 Disease Management 29

4.1 Treatment Overview 29

4.2 France 34

4.2.1 Diagnosis 34

4.2.2 Clinical Practice 34

4.3 Germany 35

4.3.1 Diagnosis 35

4.3.2 Clinical Practice 35

4.4 Italy 36

4.4.1 Diagnosis 36

4.4.2 Clinical Practice 36

4.5 Spain 37

4.5.1 Diagnosis 37

4.5.2 Clinical Practice 37

4.6 UK 39

4.6.1 Diagnosis 39

4.6.2 Clinical Practice 40

5 Competitive Assessment 42

5.1 Overview 42

5.2 Strategic Competitor Assessment 43

5.3 Product Profiles 48

5.3.1 Fibrinolytic (Thrombolytic) Drugs – Tissue Plasminogen Activator (tPA) 48

5.3.2 Clopidogrel 52

5.3.3 Brilinta (ticagrelor) 56

5.3.4 Effient (prasugrel) 60

5.3.5 Integrilin (eptifibatide) 64

5.3.6 Warfarin 67

5.3.7 Angiomax (bivalirudin) 71

5.3.8 Arixtra (fondaparinux) and the Heparins 74

5.3.9 Statins – HMG-CoA Reductase Inhibitors 78

Follow us on LinkedIn: https://www.linkedin.com/company/marketresearchreports-biz

About us

MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.


Mr. Nachiket

State Tower

90 Sate Street, Suite 700

Albany, NY 12207

Tel: +1-518-621-2074

Website: http://www.marketresearchreports.biz/

E: sales@marketresearchreports.biz